Company: ZURA
Filing Date: 2025-05-22
Form Type: CORRESP
Source: 0001104659-25-052055
Chunk: 1

Company: Zura Bio Ltd
Filing Date: 2025-05-22
Form: CORRESP
Chunk 1
---
 associated with drug substance and drug product activities
and manufacturing for torudokimab, which fees are recognized as research and development expenses as incurred. Pursuant to the WuXi Biologics
MSA, the Company entered into a cell line license agreement (the “Cell Line License Agreement”), which is further described
below.

With respect to the filing of the WuXi Biologics
MSA and Cell Line License Agreement with the Commission, we respectfully submit that these agreements are not material under Item 601(b)(10)
of Regulation S-K such that they would be required to be filed. Item 601(b)(10) of Regulation S-K defines a material contract,
in relevant part, as a “contract not made in the ordinary course of business which is material to the registrant.” This item
further states that a contract that “ordinarily accompanies the kind of business conducted by the registrant” shall be deemed
to be made “in the ordinary course” unless it falls within one of several specifically enumerated categories, in which case
it must be filed as a material contract unless it is immaterial in amount or significance. Item 601(b)(10)(ii)(B) describes one such
category as a “contract upon which the registrant’s business is substantially dependent, as in the case of continuing contracts
to sell the major part of registrant’s products or services or to purchase the major part of registrant’s requirements of
goods, services or raw materials . . . or license or other agreement to use a patent, formula, trade secret, process or trade name upon
which registrant’s business depends to a material extent.”

We are not substantially dependent upon
either of the WuXi Biologics MSA or Cell Line License Agreement. As disclosed on page 74 of our Annual Report on Form 10-K for the
fiscal year ended December 31, 2024 (the “2024 Annual Report”), we moved our existing torudokimab supply from WuXi to
the U.K. WuXi is currently conducting our drug stability study and related activities. We do not anticipate requiring additional
significant activities under the WuXi MSA or Cell Line License Agreement in the near term, and we are not obligated to use WuXi as
the manufacturer for additional torudokimab. In addition, the Cell Line License Agreement is an ordinary course arrangement commonly
entered into in connection with third-party manufacturers, under which we paid a one-time upfront fee upon execution, as